Interestingly, our data highlight that PBMCs of COVID-19 patients are more prone to release proinflammatory cytokines, such as IL-1β and IL-6, upon stimulation, thus indicating that virus infection might prime and boost the systemic inflammatory responses exposing patients to inflammation-related clinical impairment. Here, IL1B is linked to COVID-19.